Epilepsy Companion
No in-app products collected for this app.
| Rating | Price | |||
|---|---|---|---|---|
| United Arab Emirates | <1%0 | — | AED 79.99 $21.80 | |
| Afghanistan | <1%0 | — | $9.99 | |
| Antigua And Barbuda | <1%0 | — | $9.99 | |
| Anguilla | <1%0 | — | $9.99 | |
| Albania | <1%0 | — | $11.99 | |
| Armenia | <1%0 | — | $11.99 | |
| Angola | <1%0 | — | $9.99 | |
| Argentina | <1%0 | — | $9.99 | |
| Austria | <1%0 | — | €9.99 $11.56 | |
| Australia | <1%0 | — | A$14.99 $10.63 |
Description
IMPORTANT: This app is intended for use by qualified healthcare professionals only. Always seek the advice of a qualified clinician before making any medical or prescribing decisions.
Epilepsy Companion is a comprehensive evidence-based reference for the diagnosis and management of epilepsy. Built for neurologists, epileptologists, general physicians, emergency doctors, and allied health professionals.
SEIZURE CLASSIFICATION
ILAE 2017 three-level classification framework
Focal seizures: aware, impaired awareness, focal to bilateral tonic-clonic
Localisation table: seizure features mapped to brain regions
Generalised seizures: GTCS, absence, myoclonic, tonic, atonic, epileptic spasms
Terminology updates
EPILEPSY SYNDROMES
Childhood: SeLECTS, childhood absence epilepsy, Panayiotopoulos, Dravet syndrome
Juvenile: JME triad and lifetime treatment, JAE, epilepsy with GTCS alone
Adult onset: mesial temporal lobe epilepsy, frontal lobe epilepsy, late onset epilepsy
Encephalopathies: West syndrome, Lennox-Gastaut, FIRES
FIRST SEIZURE ASSESSMENT
7-step assessment protocol: was it a seizure, provoked vs unprovoked, investigations
Provoked vs unprovoked table with AED decision guidance
High-risk features favouring AED treatment after first seizure
When epilepsy is diagnosed vs single unprovoked seizure
AED DRUG REFERENCE
AED selection matrix by seizure type per NICE NG217
Focal AEDs: carbamazepine, oxcarbazepine, lacosamide, eslicarbazepine, zonisamide
Generalised AEDs: sodium valproate, ethosuximide, perampanel, rufinamide
Broad spectrum Drugs
Monitoring table
Which AEDs to AVOID
STATUS EPILEPTICUS
4-phase colour-coded protocol: 0-5 min, 5-20 min, 20-40 min, over 40 min
Phase 2: lorazepam 0.1mg/kg IV or buccal midazolam 10mg
Phase 3: levetiracetam 60mg/kg IV (ESETT trial), sodium valproate 40mg/kg IV, fosphenytoin
Phase 4: propofol, midazolam, thiopentone infusion with EEG monitoring
Refractory SE: ketamine, ketogenic diet, immunotherapy for autoimmune encephalitis
Non-convulsive SE
WOMEN AND EPILEPSY
MHRA 2024 valproate restrictions and Pregnancy Prevention Programme
Teratogenicity
Valproate PPP 6-step checklist
Lamotrigine level changes in pregnancy
Contraception table: enzyme inducers vs safe AEDs
Folic acid 5mg for all women with epilepsy on AEDs
Breastfeeding guidance by AED
DRIVING AND DVLA
Group 1 car licence: 6 visual DVLA rule cards with periods clearly stated
First seizure, established epilepsy, sleep-only seizure rule, AED withdrawal
Group 2 HGV and bus: 10-year seizure-free rule, effectively permanent bar on AEDs
Special situations
SURGICAL EVALUATION
ILAE 2010 drug-resistant epilepsy definition
6-step pre-surgical evaluation protocol
7 surgical options: temporal and extratemporal resection, corpus callosotomy
VNS, RNS, ANT-DBS (SANTE trial), LITT laser ablation
Outcome data: 60-80 percent seizure freedom after temporal lobectomy
DRUG INTERACTIONS
Enzyme inducers: 9 critical interactions including OCP failure, DOAC failure, chemotherapy
Enzyme inhibitors
AED abbreviation reference key
SUDEP
Definition, mechanism, and postictal EEG suppression
Risk factors
9-step prevention protocol
NICE NG217 mandate to counsel all patients
How to discuss SUDEP with patients and families
Resources: SUDEP Action, Epilepsy Society
SOURCES AND REFERENCES
25 plus tappable references including NICE NG217, SIGN 143, ILAE 2017 classification, MHRA 2024 valproate guidance, ESETT trial, CONVULSE trial, RAMPART trial, EURAP registry, MONEAD study, SANTE trial, MRC MESS trial, Wiebe temporal lobe surgery RCT, DVLA 2024, SUDEP Action and BNF epilepsy prescribing.
DISCLAIMER
This app is intended for use by qualified healthcare professionals only as a clinical decision-support and educational reference tool. It does not replace individual clinical assessment, local epilepsy protocols or official prescribing information.